Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas
NCT03442985 is registered in ClinicalTrials.gov with Clementia Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 22, 2018
- Completion date
- October 30, 2020
- Enrollment
- 193 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.